loading
Precedente Chiudi:
$49.82
Aprire:
$50.07
Volume 24 ore:
7,349
Relative Volume:
0.03
Capitalizzazione di mercato:
$3.16B
Reddito:
-
Utile/perdita netta:
$-54.80M
Rapporto P/E:
-42.39
EPS:
-1.1692
Flusso di cassa netto:
$-64.65M
1 W Prestazione:
-5.60%
1M Prestazione:
+1.10%
6M Prestazione:
+26.98%
1 anno Prestazione:
+15.61%
Intervallo 1D:
Value
$48.91
$51.13
Intervallo di 1 settimana:
Value
$47.33
$52.24
Portata 52W:
Value
$37.55
$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Nome
Moonlake Immunotherapeutics
Name
Telefono
41 41 510 8022
Name
Indirizzo
DORFSTRASSE 29, ZUG
Name
Dipendente
50
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
MLTX's Discussions on Twitter

Confronta MLTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
MLTX 49.56 3.16B 0 -54.80M -64.65M -1.1692
VRTX 446.87 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.28 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.30 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.22 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.67 24.49B 3.30B -501.07M 1.03B 11.54

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-15 Iniziato Wolfe Research Outperform
2023-12-08 Iniziato Citigroup Buy
2023-11-02 Iniziato Stifel Buy
2023-09-14 Downgrade Bryan Garnier Buy → Neutral
2023-08-31 Iniziato Needham Buy
2023-06-15 Iniziato Barclays Equal Weight
2023-05-01 Iniziato Guggenheim Buy
2023-03-22 Iniziato Wedbush Outperform
2023-03-09 Iniziato BTIG Research Buy
2023-02-14 Iniziato Cantor Fitzgerald Overweight
2023-02-02 Iniziato Bryan Garnier Buy
2022-11-11 Iniziato Jefferies Buy
2022-08-25 Iniziato SVB Leerink Outperform
2022-07-21 Iniziato H.C. Wainwright Buy
2022-07-07 Iniziato Cowen Outperform
Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

pulisher
Nov 20, 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN

Nov 20, 2024
pulisher
Nov 14, 2024

MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat

Nov 02, 2024
pulisher
Oct 30, 2024

MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq

Oct 30, 2024
pulisher
Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Oct 29, 2024
pulisher
Oct 26, 2024

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN

Oct 26, 2024
pulisher
Oct 25, 2024

I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet

Oct 25, 2024
pulisher
Oct 24, 2024

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St

Oct 24, 2024
pulisher
Oct 23, 2024

(MLTX) Proactive Strategies - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 17, 2024

HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria

Oct 16, 2024
pulisher
Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha

Oct 13, 2024
pulisher
Oct 12, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 10, 2024

MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex

Oct 10, 2024
pulisher
Oct 09, 2024

What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News

Oct 09, 2024
pulisher
Oct 09, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World

Oct 09, 2024
pulisher
Oct 09, 2024

Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India

Oct 09, 2024
pulisher
Oct 08, 2024

MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of Stock - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Simon Sturge Sells 171,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

MoonLake Immunotherapeutics director sells shares worth over $9m By Investing.com - Investing.com UK

Oct 08, 2024
pulisher
Oct 08, 2024

Director Simon Sturge Sells 171,000 Shares of MoonLake Immunothe - GuruFocus.com

Oct 08, 2024
pulisher
Oct 07, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3%Here's What Happened - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by The Manufacturers Life Insurance Company - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

MLTX’s price-to-free cash flow ratio: How it affects investment decisions - US Post News

Oct 04, 2024
pulisher
Oct 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 04, 2024
pulisher
Oct 01, 2024

How the (MLTX) price action is used to our Advantage - Stock Traders Daily

Oct 01, 2024

Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Moonlake Immunotherapeutics Azioni (MLTX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Sturge Simon
Director
Oct 04 '24
Sale
53.72
171,000
9,186,120
171,980
Santos da Silva Jorge
Chief Executive Officer
Feb 27 '24
Sale
55.00
62,810
3,454,550
3,043,619
Santos da Silva Jorge
Chief Executive Officer
Feb 28 '24
Sale
55.00
56,065
3,083,575
2,987,554
Santos da Silva Jorge
Chief Executive Officer
Feb 29 '24
Sale
55.89
4,740
264,919
2,982,814
Reich Kristian
Chief Scientific Officer
Feb 28 '24
Sale
55.00
31,910
1,755,050
2,925,573
Reich Kristian
Chief Scientific Officer
Feb 27 '24
Sale
55.00
29,491
1,622,005
2,957,483
Reich Kristian
Chief Scientific Officer
Feb 27 '24
Sale
55.00
29,431
1,618,705
70,071
Reich Kristian
Chief Scientific Officer
Feb 28 '24
Sale
55.00
28,090
1,544,950
41,981
Santos da Silva Jorge
Chief Executive Officer
Feb 21 '24
Sale
55.27
1,125
62,179
3,106,429
Reich Kristian
Chief Scientific Officer
Feb 20 '24
Sale
57.45
10,000
574,500
2,987,483
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):